From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?. Issue 153 (September 2015)

• Record Type: Journal Article
• Authors: Wu, Victoria Shang; Kanaya, Noriko; Lo, Chiao; Mortimer, Joanne; Chen, Shiuan
• Is Part Of: Journal of steroid biochemistry and molecular biology. Issue 153(2015)
• Page Start: 45
• Page End: 53
• Publication Date: 2015-09
• Subjects: HR+ HER2+ breast cancer -- ERα -- HER2 -- The crosstalk between ER and HER2; Steroid hormones -- Periodicals; Biochemistry -- Periodicals; Hormones -- Periodicals; Molecular Biology -- Periodicals; Hormones stéroïdes -- Périodiques; Steroid hormones; Periodicals; 572.579
• DOI: 10.1016/j.jsbmb.2015.05.005
• Languages: English
• ISSNs: 0960-0760

Abstract

Highlights: HR+ HER2+ breast cancer is a distinct subtype. The crosstalk between ER and HER2 pathways synergizes the HR+ HER2+ tumor growth. Tailored treatments for HR+ HER2+ breast cancers are waiting to be defined. The ER-HER2 crosstalk results in resistances to endocrine and HER2-targeted agents. ER and PgR are biomarkers for treatment and prognosis of HR+ HER2+ breast cancers. Abstract: Breast cancer is a heterogeneous disease. Thanks to extensive efforts from research scientists and clinicians, treatment for breast cancer has advanced into the era of targeted medicine. With the use of several well-established biomarkers, such as hormone receptors (HRs) (i.e., estrogen receptor [ER] and progesterone receptor [PgR]) and human epidermal growth factor receptor-2 (HER2), breast cancer patients can be categorized into multiple subgroups with specific targeted treatment strategies. Although therapeutic strategies for HR-positive (HR+) HER2-negative (HER2-) breast cancer and HR-negative (HR-) HER2-positive (HER2+) breast cancer are well-defined, HR+ HER2+ breast cancer is still an overlooked subgroup without tailored therapeutic options. In this review, we have summarized the molecular characteristics, etiology, preclinical tools and therapeutic options for HR+ HER2+ breast cancer. We hope to raise the attention of both the research and the medical community on HR+ HER2+ breast cancer, and to advance patient care for this subtype of disease.